Vertex Pharmaceuticals Enterprise Value Over Time
| VRTX Stock | USD 393.48 0.38 0.1% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vertex Pharmaceuticals Performance and Vertex Pharmaceuticals Correlation. Vertex |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.87 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Enterprise Value Analysis
Compare Vertex Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Sarepta Therapeutics, and Seagen Inc Enterprise Value Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMRN | 4.2 B | 4.2 B | 12.9 B | 12.9 B | 12.9 B | 15.4 B | 15.4 B | 15.4 B | 15.4 B | 16.6 B | 16.6 B | 16.6 B | 16.6 B | 15 B | 9.8 B |
| SRPT | 51.1 M | 59.1 M | 422.9 M | 433.9 M | 1.2 B | 1.2 B | 1.2 B | 12 B | 12 B | 12 B | 12 B | 12 B | 12 B | 10.8 B | 11.3 B |
| ALNY | (13.5 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (18 M) | (18.9 M) |
| NTLA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EDIT | 270.8 M | 270.8 M | 270.8 M | 270.8 M | 270.8 M | 706.5 M | 372.7 M | 1.1 B | 969.1 M | 1.3 B | 4 B | 1.6 B | 511.5 M | 682.4 M | 921.9 M |
| BEAM | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 3.8 B | 4.3 B | 2.7 B | 1.8 B | 3.5 B |
| DNA | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 14.5 B | 12.7 B | 11.9 B | 2 B | 2.3 B | 2.1 B |
| BNTX | 2.6 B | 2.6 B | 2.6 B | 2.6 B | 2.6 B | 2.6 B | 2.6 B | 2.6 B | 2.5 B | 5.9 B | 14.7 B | 20.6 B | 20.6 B | 11.5 B | 7.7 B |
| MRNA | 7 B | 7 B | 7 B | 7 B | 7 B | 7 B | 7 B | 6.9 B | 613.7 M | 6.4 B | 37.4 B | 37.4 B | 37.4 B | 33.7 B | 35.4 B |
| REGN | 257.9 M | 5 B | 19.2 B | 30.6 B | 62.1 B | 62.1 B | 42.6 B | 42.6 B | 42.6 B | 42.6 B | 42.6 B | 42.6 B | 42.6 B | 38.4 B | 40.3 B |
| VKTX | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 19.6 M | 99.9 M | 569.4 M | 569.4 M | 380 M | 380 M | 380 M | 342 M | 174.7 M |
| PTCT | 217.2 M | 217.2 M | 236.1 M | 202.3 M | 1.3 B | 844.9 M | 238 M | 606.1 M | 1.5 B | 2.5 B | 4.2 B | 2.5 B | 3 B | 1.9 B | 1.2 B |
| KRYS | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 6.8 M | 129.1 M | 696.3 M | 1.2 B | 1.2 B | 1.9 B | 3 B | 3.2 B |
| MDGL | 26.6 M | 207 M | 466.8 M | 228.9 M | 228.9 M | 37.1 M | 37.1 M | 932.4 M | 1.2 B | 1.4 B | 1.7 B | 1.4 B | 4.7 B | 4.3 B | 4.6 B |
| CRSP | 411.9 M | 411.9 M | 411.9 M | 411.9 M | 411.9 M | 295.2 M | (67.2 M) | 698.9 M | 913.6 M | 2.4 B | 9 B | 5.1 B | 3.2 B | 2.9 B | 1.9 B |
| CRBU | 938.2 M | 938.2 M | 938.2 M | 938.2 M | 938.2 M | 938.2 M | 938.2 M | 938.2 M | 938.2 M | 938.2 M | 964.3 M | 669.2 M | 351.2 M | 399.2 M | 730.9 M |
| VERV | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.7 B | 1.7 B | 1 B | 763.3 M | 1.5 B |
Vertex Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Sarepta Therapeutics, and Seagen Inc Enterprise Value description
Enterprise Value (or EV) is usually referred to as Vertex Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Vertex Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of Vertex Pharmaceuticals value than its market capitalization because it takes into account all of Vertex Pharmaceuticals existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.My Equities
My Current Equities and Potential Positions
| Vertex Pharmaceuticals | VRTX |
 | Pharmaceutical ProductsFama & French Classification |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 393.48
Check out Vertex Pharmaceuticals Performance and Vertex Pharmaceuticals Correlation. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Vertex Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.